ValueQ3, 24Q4, 24Q1, 25Q2, 25Q3, 25TTMSelling/general/admin expenses39.98 M36.92 M43 M39.51 M41.85 M161.28 MResearch & development10.4 M10.98 M12.56 M7.24 M14.13 M44.9 MOperating income16.03 M-36.47 M22.1 M7.09 M9.96 M2.68 MNon-Operating Income, Total1.58 M1.21 M1.07 M666 K677 K3.62 MInterest expense, net of interest capitalized15.08 M16.42 M19.43 M20.49 M22.05 M78.39 MNon-Operating Income, excl. Interest Expenses-15.08 M-16.42 M-19.43 M-20.49 M-22.05 M-78.39 MUnusual income/expense1.58 M1.21 M1.07 M666 K677 K3.62 MPretax income2.53 M-51.69 M3.74 M-12.72 M-11.41 M-72.09 MEquity in earnings——————Taxes000000Non-controlling/minority interest——————After tax other income/expense——————Net income before discontinued operations29.52 M-100.73 M40.45 M12.72 M31.33 M-16.21 MDiscontinued operations——————Net income29.52 M-100.73 M40.45 M12.72 M31.33 M-16.21 MDilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders29.52 M-100.73 M40.45 M12.72 M31.33 M-16.21 MBasic earnings per share (Basic EPS)-0.15-0.16-0.21-0.06-0.16-0.59Diluted earnings per share (Diluted EPS)-0.15-0.14-0.21-0.06-0.16-0.57Average basic shares outstanding194.93 M187.18 M196.13 M197.55 M200.74 M781.59 MDiluted shares outstanding194.93 M187.18 M196.13 M197.55 M200.74 M781.59 MEBITDA——————EBIT——————Cost of revenue——————Other cost of goods sold——————Depreciation & amortization (cash flow)473 K236 K725 K847 K873 K2.68 M
Esperion Therapeutics Inc
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.